P atients with diabetes are at increased risk for the development of cardiovascular diseases and death from cardiovascular causes. 1 In addition, diabetes is associated with a variety of cardiac alterations, including left ventricular (LV) hypertrophy and reduced systolic and diastolic function. 2, 3 After myocardial infarction (MI), diabetic patients are at increased risk for adverse events, including death, recurrent MI, and heart failure (HF). 4, 5 LV remodeling-as indicated by LV enlargement-is also associated with an increased risk of the same adverse events after MI. 6 Remodeling after MI is a heterogeneous process and is influenced by a variety of factors, including infarct size, 7 coronary reperfusion, 8, 9 and ACE inhibitor therapy, 6, 10 and has been thought to represent an important component in the progression to HF in patients after MI. 11 We studied patients enrolled in the Survival and Ventricular Enlargement (SAVE) study 12 to test the hypothesis that the increased incidence of HF in diabetic patients after MI was associated with a greater propensity for LV enlargement or remodeling.
Methods

Patients
The Survival And Ventricular Enlargement (SAVE) trial enrolled 2231 patients with LV dysfunction (ejection fraction Յ40%) after MI and randomized these patients to receive either captopril or placebo. 12 Patients enrolled in the echocardiographic substudy (nϭ512) underwent two-dimensional echocardiography at a mean of 11.1Ϯ3.2 days after MI (baseline) and again at 3 months, 1 year (nϭ426), and 2 years after MI (nϭ387). 6 Echocardiograms from baseline, 1 year, and 2 years were analyzed in all patients; echocardiograms at 3 months were only analyzed in patients who died before the subsequent study. The demographics of the echocardiographic participants were similar to the overall study group. 6 Diabetic patients comprised 22% of the entire study cohort and 19.5% of the echocardiographic cohort at baseline (nϭ512), as assessed at the time of study enrollment. Diabetic patients comprised 71 of 387 (18.3%) patients surviving to the second-year echocardiogram.
Echocardiographic Assessment
All two-dimensional echocardiograms were analyzed by the core laboratory at the Brigham and Women's Hospital. Endocardial borders were digitized manually at end-diastole and end-systole from apical 4-chamber, 2-chamber, and short-axis views. 6 The average cavity area from the apical views and the short-axis views were summed. The change in the combined end-diastolic cavity area from baseline (mean, 11 days after MI) to 2 years was used as a measure of ventricular enlargement, a component of LV remodeling. Ejection fraction was calculated from area measurements using the arealength method applied to the average apical area. 13 Average wall thickness was derived from the short-axis LV areas by subtracting the endocardial cavity area from the total epicardial area and calculating average wall thickness. In a subset of patients, the E and A waves were measured from the mitral inflow Doppler echocardiograms, and E/A ratios were calculated. Patients were categorized into 1 of 3 E/A ratio groups: E/A Ͻ1.0; E/A 1.0 to 1.5; or E/A Ͼ1.5.
Clinical and Outcome Measures
The development of HF was defined as either hospitalization for HF (as indicated on a case-report form by the site investigator as being the primary reason for hospitalization) or a clinical diagnosis of HF determined by the patient's physician to be of sufficient severity to require discontinuation of study medication and placement on open-label ACE inhibitor. 12 Concomitant medication usage on follow-up was assessed by reviewing medication usage at each follow-up visit and determining the percentage of visits in which patients were taking various concomitant medications.
Statistical Analysis
Comparisons of echocardiographic parameters between diabetic and nondiabetic patients were made with the Student's t test. The Cox proportional hazards model was used to determine the predictive value of ventricular enlargement in the development of HF and to explore the interaction between diabetes and ventricular enlargement in the development of HF. An interaction term combining diabetes and change in diastolic area was used to determine whether diabetes altered the relationship between remodeling and HF.
Results
HF developed in 30% of diabetic compared with 17% of nondiabetic patients (PϽ0.001) enrolled in the echo cohort, proportions that were similar in the entire study cohort. In patients who survived to the 2-year echocardiogram (nϭ387), HF developed in 29.6% of diabetic and 13.9% of nondiabetic patients (Pϭ0.001). Diabetic patients were slightly older and more likely to be female (Table 1) . Baseline systolic blood pressure and heart rate were slightly higher in diabetic patients. Whereas diuretic and digitalis use was higher in diabetic patients at baseline and on follow-up visits, use of ␤-blocker therapy was similar in both groups at baseline and during the follow-up period. Importantly, baseline echocardiographic determination of LV areas, infarct segment length, and ejection fractions showed no difference between diabetic and nondiabetic patients.
Two-year echocardiograms were performed in 387 patients, 316 nondiabetic and 71 diabetic ( Table 2) . LV diastolic area increased to a greater extent in nondiabetic than in diabetic patients over 2 years (Table 2 ; Pϭ0.047). Ejection fraction remained similar in the diabetic and nondiabetic groups at 2 years.
The 65 patients who developed HF at any time during follow-up demonstrated increased diastolic enlargement (Table 2). Diastolic LV enlargement was greater in nondiabetic patients who developed HF (nϭ44) compared with diabetic patients (nϭ21) who developed HF (10.1Ϯ12.4 versus 3.7Ϯ13.1, Pϭ0.062). Changes in systolic enlargement paralleled changes in diastolic enlargement, with significantly greater systolic enlargement in nondiabetic compared with diabetic patients (12.5Ϯ13.4 versus 4.4Ϯ13.7, Pϭ0.027). Whereas ejection fraction at 2 years was significantly reduced in patients who developed HF compared with patients who did not develop HF (27.0Ϯ8.5% versus 36.0Ϯ10.3%, PϽ0.0001), the ejection fraction among diabetic patients who (Figure; Pϭ0.018) . In a Cox proportional hazards analysis, dilatation by 2 years was predictive of subsequent HF in the nondiabetic group (Pϭ0.001) but not in the diabetic group (Pϭ0.85), even after adjusting for history of hypertension, prior myocardial infarction, age, treatment group, and history of smoking, diuretic, and digoxin use and after excluding patients with recurrent myocardial infarction before the development of HF. The development of HF was modified by the presence of diabetes, with a significant interaction between diabetes and ventricular enlargement in the development of subsequent HF (Pϭ0.011).
To clarify the effect of diastolic function and LV compliance in this population, we assessed E/A ratios and average wall thickness in diabetic compared with nondiabetic patients at baseline, 1-year, and 2-year echocardiograms. E/A ratios were slightly higher in diabetic patients only at baseline (1.46Ϯ0.81 versus 1.23Ϯ0.63, Pϭ0.037), whereas absolute E/A ratios were similar at subsequent examinations. The proportions of diabetic and nondiabetic patients in each of 3 E/A ratio categories were similar at all time points. Diabetic patients, but not nondiabetic patients, in the highest E/A category (E/A Ͼ1.5) were more likely to develop HF (OR, 6.9; 95% CI, 2.1 to 22.5). Wall thickness, similar between the 2 groups at baseline (diabetic, 1.20Ϯ0. 16 
04).
Because mortality before the second-year echo was higher in diabetic than in nondiabetic patients (27% versus 18%), we assessed the effect of survivor bias on our results by comparing LV area on the last available echocardiographic study (3-month or 1-year echocardiograms) in patients who died or did not have the 2-year follow-up study. In the small number of patients who did not have the 2-year echocardiogram, there were no differences between those who were diabetic and nondiabetic in the degree of ventricular dilatation from baseline to each of these time points (Table 3) , arguing against increased dilatation in diabetic patients who did not have the 2-year echocardiogram.
Discussion
Patients with diabetes are at increased risk for the development of atherosclerosis and the progression to end-stage heart disease. While initially at increased risk for developing MI, patients with diabetes have a higher subsequent risk of developing HF. 14 In the SAVE echocardiographic cohort, baseline demographic and echocardiographic assessments did not explain the increased propensity to develop HF in diabetic patients. The results of this study suggest that although HF develops at twice the rate in diabetic than in nondiabetic patients after MI, and although the development of HF is associated with increased ventricular enlargement in both groups, the incidence and extent of LV enlargement are significantly less in the diabetic patient. Thus, the increased incidence of HF after MI in patients with diabetes cannot be explained by an increased propensity for LV enlargement. Relation between change in LV combined end-diastolic area between baseline and 2 years in nondiabetic and diabetic patients and development of HF after 2 years.
Solomon et al Ventricular Remodeling in Diabetic Patients
Diabetes is associated with a variety of ultrastructural changes in the myocardium. This so-called diabetic cardiomyopathy is characterized by increased myocardial fibrosis, 15 LV hypertrophy, 3 and increased collagen content. 16 -18 The increased collagen accumulation in the diabetic myocardium has been linked to alterations in both diastolic and systolic function. 19 -22 In addition, recent evidence suggests that both hyperglycemia and insulin resistance may contribute to adverse myocardial metabolism, resulting in abnormal systolic and diastolic function. 23 Although diabetes is well established to impact survival adversely after MI, 4 there is relatively little known about the effects of diabetes on post-MI ventricular remodeling. Although remodeling is itself a complex process involving changes in ventricular size, shape, and mass, ventricular enlargement has been routinely used as a surrogate for remodeling. 6, 7 One small study of 49 patients after MI suggested worsening of ventricular function and increased ventricular dilatation in diabetic compared with nondiabetic patients, 24 whereas another study of 100 patients found no significant differences in the extent of ventricular enlargement after MI in diabetic compared with nondiabetic patients. 25 Our data suggest that after MI, diabetes was not associated with greater ventricular enlargement despite an increased incidence of HF. The observation that baseline infarct segment length and ejection fraction were similar in nondiabetic and diabetic patients suggests that the higher risk of HF in diabetic patients was not simply the result of larger infarcts. Likewise, recurrent myocardial infarction, more frequent in diabetic patients in our population, also did not account for the observed increased risk of HF in this group.
Although abnormalities of systolic function occur in people with diabetes, substantial evidence implicates diastolic dysfunction as a primary abnormality in these patients 26, 27 and a potential explanation for the alterations in ventricular remodeling that is observed. Diastolic abnormalities have been attributed to both increases in myocardial collagen content and to abnormalities of calcium handling 19, 28, 29 and contribute to the increased risk for HF among diabetic patients in large epidemiologic studies. 30 In the present study, systolic function was similar in diabetic and nondiabetic patients at baseline and at 2 years, suggesting that progressive systolic dysfunction could not account for the increased incidence of HF. 22 These findings are consistent with those of the GUSTO-I trial, in which early systolic function (up to day 7) was no worse in diabetic patients despite a significantly higher mortality. 31 In addition, a higher proportion of diabetic than nondiabetic patients had a history of hypertension or were receiving antihypertensive therapy at baseline, although these findings could not explain the decreased remodeling seen in diabetic patients. We also observed slightly greater LV wall thickness in diabetic patients on follow-up, which in the setting of decreased overall ventricular size may be associated with higher relative wall thickness and thus higher filling pressures. 32 Furthermore, diabetic patients in the highest E/A ratio categorywhich may include patients with so-called "restrictive" filling-were more likely to develop HF, raising the possibility that restrictive physiology may be part of the diabetic cardiomyopathic process. Taken together, these data support a possible increased predisposition to diastolic dysfunction in the diabetic group.
LV enlargement occurs as a pathophysiologic adaptation to the loss of stroke volume after MI. 33 Although the geometric changes that accompany active remodeling result in improved stroke volume, this adaptation is nevertheless associated with an increased risk of adverse events and death after MI. 6 The finding that diabetic patients may develop HF with less enlargement than nondiabetic patients is contrary to the established notion that ventricular enlargement represents an intermediate step in the development of HF in all patients. These data suggest that the diabetic heart may be less capable of adapting to the loss of stroke volume by dilating than the nondiabetic heart and thus may be less able to restore stroke volume after MI. A decreased ability to remodel in the diabetic patient would likely be associated with increased filling pressures compared with a nondiabetic patient with the same degree of contractile loss. This hypothesis is supported by the finding that in a subset of the SAVE population, N-terminal proatrial natriuretic factor was higher in diabetic than in nondiabetic patients. 34 Our data support the concept that the decreased extent and incidence of ventricular enlargement in diabetic patients may contribute to the greater propensity to develop symptomatic HF in this population.
The SAVE trial demonstrated that the ACE inhibitor captopril could reduce mortality and development of HF and attenuate ventricular enlargement in patients with LV dysfunction after MI. ACE inhibitors have been shown to be equally effective in diabetic and nondiabetic patients. 35 In the present study, the relationship between diabetes and enlargement was comparable regardless of treatment assignment.
Limitations
Although the observation of decreased ventricular enlargement in the diabetic group was observed in both patients who survived and patients who died, it is possible that ventricular 
Conclusion
The results of this study suggest that after MI, patients with diabetes demonstrate less LV enlargement than patients without diabetes, and that diabetic patients who develop HF do so after less ventricular enlargement. These data suggest that diabetic patients may have a decreased capacity to remodel the left ventricle after MI and therefore develop HF at lower ventricular volumes than nondiabetic patients with similar-sized infarcts.
